Early absolute lymphocyte count (ALC) recovery at day 15 post-autologous stem cell transplantation (ASCT) is a powerful prognostic indicator for survival in multiple myeloma and non-Hodgkin's lymphoma. The relationship of ALC with clinical outcomes in metastatic breast cancer is unknown. We evaluated all 29 patients with metastatic breast cancer who underwent ASCT at the Mayo Clinic, Rochester, Minnesota, from 1994 to 1999. The ALC threshold was set at 500 cells/l on day 15 post-ASCT based on previous experience with hematologic malignancies. All patients were followed for a minimum of 2 years or until death, with a median follow-up for living patients of 2.25 years. Of the 29 patients, 17 have died with disease progression, two are alive and have progressed, and 10 are alive without progression. The median overall and progression-free survival times were significantly better for the 20 patients with ALC у500 cells/l compared with the nine patients with ALC Ͻ500 cells/l (not reached vs 14 months, P Ͻ 0.0001; 24 vs 7 months, P Ͻ 0.0015, respectively). In conclusion, ALC у500 cells/l on day 15 post-ASCT was associated with significantly better survival in patients with metastatic breast cancer, suggesting the importance of early immune recovery post-ASCT in these patients. Bone Marrow Transplantation (2001) 28, 865-871. Keywords: absolute lymphocyte count recovery; autologous stem cell transplantation; metastatic breast cancer Randomized studies between high-dose therapy (HDT) and conventional chemotherapy for metastatic breast cancer have shown no difference in survival. 1 The largest of the four metastatic breast cancer trials, the Philadelphia Intergroup study (PBT1), 2 entered a total of 535 patients. With a median follow-up of 37 months, there was no significant difference in the overall survival (OS) at 3 years (32% in the transplant group and 38% in the conventionalchemotherapy group, P = 0.23). There was also no significant difference in the median time to diverse progression (9.6 months for the transplant group and 9 months for conventional-dose chemotherapy, P = 0.31).
Intergroup study (PBT1), 2 entered a total of 535 patients. With a median follow-up of 37 months, there was no significant difference in the overall survival (OS) at 3 years (32% in the transplant group and 38% in the conventionalchemotherapy group, P = 0.23). There was also no significant difference in the median time to diverse progression (9.6 months for the transplant group and 9 months for conventional-dose chemotherapy, P = 0.31).
High relapse rates post-ASCT have been attributed to the inability of HDT to eradicate minimal residual disease. Lower relapse rates observed after allogeneic bone marrow transplantation (ABMT) in malignant hematological conditions have been attributed to the adoptive graft-versustumor (GVT) immune response. 3 Studies in ABMT have demonstrated that early absolute lymphocyte count (ALC) recovery post-ABMT is associated with prolonged survival. Using an ALC cut-off value of 200 cells/l at day 29 post-ABMT in 188 acute myelogenous leukemia (AML) patients, Powles et al 4 demonstrated a 3-year relapse probability of 42% for ALC Ͻ200 cells/l vs 16% for ALC 200 cells/l (P Ͻ 0.004). Pavletic et al 5 analyzed ALC in 41 patients post-ABMT (AML, chronic myelogenous leukemia, myelodysplastic syndrome, Hodgkin's disease, chronic lymphocytic leukemia). The OS at 1 year with an ALC at day 17 post-ABMT of у500 cells/l was 79% vs 19% for ALC Ͻ500 cells/l (P Ͻ 0.0024).
We have recently reported the association between ALC recovery and prolonged survival in multiple myeloma (MM) and non-Hodgkin's lymphoma (NHL) patients post-ASCT. 6 In our study of 230 patients (126 MM and 104 NHL), the median OS and progression-free survival (PFS) for the MM group were significantly better for patients with ALC у500cells/l vs ALC Ͻ500 cells/l (33 months vs 12 months, P Ͻ 0.0001; 16 months vs 8 months, P Ͻ 0.0001, respectively). For the NHL patients, the median OS and PFS were significantly better for patients with ALC у500 cells/l vs ALC Ͻ500 cells/l (not yet reached vs 6 months, P Ͻ 0.0001; not yet reached vs 4 months, P Ͻ 0.0001, respectively). Multivariate analysis comparing ALC to all known prognostic factors in MM and NHL demonstrated day 15 ALC post-ASCT as a powerful, inde-pendent prognostic indicator for OS and PFS rates for both groups of patients.
Based on our previous findings in MM and NHL, we conducted a retrospective analysis of ALC at day 15 post-ASCT in women with metastatic breast cancer receiving marrow-ablative therapy followed by ASCT. The purpose of this study was to determine if early ALC recovery was associated with a better prognosis in this population of patients thus providing a basis for hypothesis generation relating to the importance of immune function in the setting of ASCT.
Materials and methods

Patient population
Thirty-two consecutive patients with metastatic breast cancer underwent HDT and ASCT at the Mayo Clinic Rochester, MN, USA, between February 1994 and April 1999. Based on their experimental use of samarium as the conditioning regimen, three patients were excluded from the study to minimize bias. A total of 29 patients with a metastatic breast cancer from two different studies were analyzed in the study. Data from transplant recipients were collected prospectively and entered into a computerized database. Response to therapy, relapse, and survival data are updated continuously. No patients were lost to followup. All patients gave written, informed consent to allow utilization of their medical records for medical research. Approval for the retrospective review of these records was obtained from the Mayo Clinic Institutional Review Board and was in accordance with US federal regulations and the Declaration of Helsinki.
Conditioning regimens and stem cell source
All patients underwent conditioning with STAMP V (cyclophosphamide 1.5 g/m 2 /day; carboplatin 200 mg/m 2 / day; and thiotepa 125 mg/m 2 /day on days −7, −6, −5, and −4). Of the patients transplanted with the STAMP V conditioning regimen, 14 participated in the PBT1 study, 14 participated in a phase II randomized trail of peripheral blood stem cell mobilization comparing G-CSF or GM-CSF with or without Flt-3 ligand, and one patient was transplanted off protocol. In the phase II Flt-3 ligand study, three patients received G-CSF alone, five Flt-3 plus G-CSF, and six Flt-3 plus GM-CSF. Hematologic engraftment was defined at the first day of an absolute neutrophil count (ANC) у500 cells/l times 3 consecutive days. Platelet engraftment was defined as a platelet count of у20 × 10 9 /l independent of transfusion support. ALC threshold (immunologic engraftment) was determined at 500 cells/l on day 15 after transplantation. Twenty-three patients underwent peripheral blood stem cell (PBSC) transplantation. Twelve patients, not receiving Flt-3, received PBSC mobilized with G-CSF and six patients received unmobilized bone marrow (BM).
Supportive care
All patients received granulocyte colony-stimulating factor (G-CSF) after transplantation. Different prophylactic antibiotics, antifungal, antiviral medications and transfusion requirements were used according to bone marrow transplant supportive care guidelines during the transplant phase.
Eligibility criteria
Eligibility criteria for patients enrolled in the PBT1 study included age between 18 and 60 years; adequate renal and hepatic function; a normal cardiac ejection fraction; ECOG performance status of 0 or 1; locally recurrent or distant metastatic breast cancer; and no previous chemotherapy for metastatic disease. If a patient had received adjuvant chemotherapy after surgical treatment of the primary tumor, the adjuvant therapy had to have been concluded more than 6 months before enrollment in the study. Patients could be premenopausal or postmenopausal, and if they had a positive estrogen-receptor assay, they must have had at least one prior hormonal treatment unless life-threatening visceral disease was present. Patients were excluded if they had metastases to the central nervous system, an uncontrolled infection, or any illness that would preclude the possibility of subsequent stem cell transplantation. 2 For the phase II Flt-3 ligand study, the inclusion criteria included patients with breast cancer eligible to undergo stem cell transplantation, who had received one course of induction chemotherapy for metastatic disease. Patients could also previously have received adjuvant chemotherapy; be of age у16 years old; with no prior cytokine therapy, chemotherapy, radiation, or investigation drugs during 4 weeks prior to mobilization; have adequate renal and hepatic function; and performance status Karnofsky у60%. Patients were not eligible if they had had prior malignancies within 5 years; active infection; prior stem cell transplantation; chemotherapy during mobilization for stem cell transplantation; or concurrent chemotherapy, radiation, or immunotherapy. The only patient treated off protocol was required to be a candidate for stem cell transplantation and to show chemosensitive disease prior to transplantation.
Response and survival
Response to therapy was defined in the PBT1 study as complete remission (no evidence of disease), a partial remission (reduction of at least 50% using longest perpendicular diameters in the size of all measurable tumor areas in more than 50% of involved organ sites), or a partial remission restricted to bone (bone lesions that remained stable on bone scans and X-ray films for a period of at least 8 weeks in association with an improved in the ECOG performance status, a decrease in the requirement for analgesia, or both). For patients in the Flt-3 ligand study and the patient treated off protocol, a complete remission was defined as no evidence of disease. Partial remission was defined as a reduction of at least 50% of the product of perpendicular diameters. Progression of disease was defined as a greater than 25% increase in the product of perpendicular diameters or new lesions.
OS time was measured from the date of transplantation to the date of death or last follow-up. PFS time was defined as time from transplantation to disease progression, relapse, or death.
Statistical analysis
OS and PFS times were analyzed using the method of Kaplan and Meier. 7 Differences between survival curves were tested for statistical significance using the two-tailed log-rank test. The Cox proportional hazards model 8 was used to assess ALC as a prognostic factor for post-transplant OS and PFS rates, as well as to adjust for other known prognostic factors.
Risk ratios reported are for risks associated with patients having high (Ͼ500 cells/l) vs low (Ͻ500 cells/l) ALC values. Prognostic factors tested included: age 45 years old, Karnofsky performance score Ͻ90%, absence of hormone receptors, prior use of adjuvant chemotherapy, disease-free survival interval after adjuvant chemotherapy Ͻ18 months, metastases to the liver vs others, CR vs PR to standarddose chemotherapy prior to transplantation, pre-vs postmenopausal status, tamoxifen use post-ASCT, number of metastatic sites у3, type of graft (BM vs PBSC), stem cell mobilization cytokines (Flt-3 ligand vs G-CSF), her-2 neu, ANC у500 cells/l, platelet у20 × 10 9 /l, metastases to the liver vs others, and adjuvant radiation. The cut-off of ALC у500 cells/l was based on our previous study. 6 This choice of cut-point was supported by the data, as it yielded the greatest differential in survival based on 2 values from log-rank tests. The 2 and Fisher's exact tests were used to determine relationships between nominal variables; nonparametric tests were used for continuous variables. All P values represented are two-sided and statistical significance was declared at P Ͻ 0.05.
Results
Twenty-nine patients with metastatic breast cancer who underwent ASCT were identified for the study with a median age of 49 years (range 31-65). Patient characteristics are described in Table 1 . None of the patients had central nervous system metastases prior to transplantation. Table 2 shows the distribution of reported risk factors 9 associated with increased risk of treatment failure according to ALC recovery. Patients received a median of two chemotherapy regimens prior to ASCT (range 1-4), including the chemotherapy regimens required to participate in the prospective protocols PBT1 or Flt-3 ligand. Eleven patients received one pre-transplant chemotherapy regimen, 15 two pre-transplant chemotherapy regimens, two three pre-transplant chemotherapy regimens, and one four pre-transplant chemotherapy regimens. The median disease-free survival time from time of diagnosis to developing metastatic disease was 12 months (range 0-72). The median time from diagnosis to undergoing autologous stem cell transplantation was 24 months (range 5-74). Ten patients received radiation therapy pre-transplantation: five after their lumpectomy surgery, two for chest wall recurrence, two for chest wall and supraclavicular lymph node involvement, Bone Marrow Transplantation Table 1 Patients baseline characteristics according to absolute lymphocyte count (ALC) recovery at day 15 post-ASCT
Age (years) 
Overall survival and progression-free survival
By March 2001, 17 deaths had occurred among the 29 patients in the study, due to recurrent or progressive disease. This included eight deaths in the 20 patients with ALC у500 cells/l and nine deaths in the nine patients with ALC Ͻ500 cells/l. Of the 12 surviving patients whose ALC у500 cells/l, two had progressed and remained alive. Ten patients remained alive without recurrence or progression of disease (10 with ALC у500 cells/l and none with ALC Ͻ500 cells/l). There was no transplant-related mortality. One patient developed E. coli bacteremia and another Streptococcus viridans bacteremia. One patient developed acute cholecystitis and three had line-related thrombosis. There was no significant difference in the supportive care including antibiotics, growth factors, or transfusion requirements. None of the patients developed autologous graft-versus-host disease. All patients were followed for a minimum of 2 years or until death, with a median follow-up for living patients of 2.25 years and a maximum of 3.5 years. The median OS ( Figure 1 ) and PFS ( Figure 2) were significantly greater for patients with ALC у500 cells/l vs ALC Ͻ500 cells/l (not yet reached vs 14 months, P Ͻ 0.0001; 24 vs 7 months, P Ͻ 0.0015, respectively).
Univariate and multivariate analysis (Table 3)
ALC, stem cell source (BM vs PBSC), stem cell mobilization cytokines (Flt-3 vs G-CSF), number of metastatic sites у3, and pre-vs post-menopausal status prior to transplantation were significant predictors of OS and PFS in the univariate analyses. On multivariate analysis, ALC was an independent predictor for OS (RR = 0.28, P Ͻ 0.0003) and PFS (RR = 0.44, P Ͻ 0.0026), when compared with the significant predictors identified on univariate analysis, including stem cell source (BM vs PBSC), stem cell mobilization cytokines (Flt-3 vs G-CSF), number of metastatic sites у3, and pre-vs post-menopausal status prior to transplantation. There were no statistical differences between CR vs PR status prior to transplantation for OS (P = 0.46) and PFS (P = 0.32). Figure 1 The median overall survival for the cohort group is 24 months. The median overall survival for the group of patients with ALC у500 cells/l has not been reached vs 14 months for patients with ALC Ͻ500 cells/l (P Ͻ 0.0001). The median progression-free survival for the cohort group is 12 months. The median progression-free survival for the group of patients with ALC у500 cells/l is 24 months vs 14 months for patients with ALC Ͻ500 cells/l (P Ͻ 0.0015).
Discussion
Our data show that ALC (у500 cells/l on day 15) post-ASCT has a significant association with better survival in patients with metastatic breast cancer. This is the first study describing the association of prolonged survival and ALC post-ASCT in patients with metastatic breast cancer.
Possibly due to our small sample size and resulting lack of power in identifying all but overwhelmingly large differences, we identified no correlation between ALC and either pre-transplant intensity of treatment, ANC, or stem cell characteristics as indicated by the MNC or CD34 cell counts. No correlation between ALC and number of pretransplant chemotherapy regimens, or the re-infused stem cells (CD34 or MNC) was observed in our previous study in patients with MM and NHL which involved 230 patients. This suggests the possibility that the repopulating lymphocytes post-ASCT may be derived from sources other than the transplanted stem cells including host lymphocytes surviving the conditioning regimen and/or lymphocytes present in the autograft.
Our multivariate analysis shows ALC recovery at day 15 post-ASCT as a powerful, independent prognostic factor for overall and progression-free survival in patients with metastatic breast cancer. The small sample size in our study requires larger studies to confirm the prognostic impact of ALC recovery post-ASCT in patients with breast cancer.
A potential explanation for the survival advantage associated with ALC recovery post-ASCT in metastatic breast cancer patients is the possibility that early immune-reconstitution may have a protective effect against residual disease progression. This is analogous to the GVT effect in ABMT recipients reported in a few cases of breast cancer where the donor immune system is considered to be responsible for eradication of residual disease in the host. 10, 11 While reappearance of neutrophils and platelets is often considered the endpoint of hematologic recovery after ASCT, immunological reconstitution is a gradual process that may not be completed until months to years post transplantation. 12 Several studies post-ASCT for hematologic
Bone Marrow Transplantation malignancies have demonstrated delayed immunologic recovery, both qualitative and quantitative for B and T cells. [13] [14] [15] [16] [17] This same phenomenon of delayed B and T cell recovery post-ASCT has been reported in patients with metastatic breast cancer. Avigan et al 18 demonstrated abnormalities in T cell phenotype and function in patients followed up to 12 months post-ASCT. Most of the patients experienced an inversion of the CD4/CD8 ratio as observed in hematologic malignancies and a decreased T cell proliferation in response to the mitogen phytohemagglutinin (PHA). A positive delayed type hypersensitivity (DTH) response to candida antigen was seen in 85% of patients prior to HDT. In contrast, only 32% of patients demonstrated an intact response at 1 month and with an 80% response at 12 months post-ASCT, thus describing an anergic immunologic state early post-ASCT. The humoral arm of the immune system showed normal levels of IgG and IgA at 6 months post-ASCT.
Studies of immuno-reconstitution post-ASCT have shown that natural killer (NK) cells recover normal absolute and relative numbers within 1 month after transplant. [19] [20] [21] [22] Our own data demonstrate normal absolute NK cell counts and function at 2 weeks post-ASCT in patients with MM and NHL. 23 Avigan et al 18 demonstrated normal qualitative and quantitative NK cell recovery at 1 month post-ASCT in advanced breast cancer. These studies confirm that recovery of NK cell activity after ASCT occurs sooner than B or T cell recovery and suggest that NK cell recovery is independent of disease type (MM, NHL, and breast cancer). In addition, early NK cell recovery has been reported after standard chemotherapy, 24 autologous stem cell transplantation, 14 and allogeneic bone marrow transplantation. 25 Maturation of NK cells can occur in the absence of a functional thymus in mice and humans, perhaps accounting for the prompt NK cell recovery. 26 30 showed an increased number of NK cells in the tumor-infiltrating leukocytes (TIL) in tumor samples of patients with breast cancer. IL-2 was able to enhance the cytotoxicity of TIL (NK cells) against the ZR 75-1 breast cancer cell line. Based on these data, it is reasonable to hypothesize that NK cells may play an important immuno-surveillance role early after ASCT for metastatic breast cancer. The survival advantage observed with patients achieving a higher ALC recovery in our study suggests the importance of enhancing early immunologic recovery (ie NK cells). In 43 women with breast cancer Burns et al 31 demonstrated enhanced NK cells numbers in the stem cell graft and cytotoxic function against human breast cancer cell line MCF-7 using IL-2 and G-CSF combination during stem cell mobilization. The enhanced NK cell activity was observed only up to 2 weeks after autologous stem cell transplantation of the patients mobilized with IL-2 and G-CSF. To prolong the duration of the graft-versus-tumor effect mediated by the IL-2 and G-CSF mobilized graft it may be beneficial to consider additional post transplantation immunomodulation. 31 Immunologic graft engineering will help develop specific graft-versus-tumor effects in the hope of preventing tumor recurrence after ASCT. Due to the retrospective nature of this study, we do not know the lymphocyte subsets involved in the stem cell graft or ALC recovery at day 15 post-ASCT and their relationship to clinical outcome. Identification of the lymphocytes subsets involved in the stem cell graft and in the ALC at day 15 post-ASCT and their relationship to clinical outcome is the subject of an ongoing study in patients with non-Hodgkin's lymphoma.
In conclusion, ALC у500 cells/l on day 15 post-ASCT is associated with significantly improved survival in patients with metastatic breast cancer. The observed clinical benefit of early ALC recovery may be related to a GVT effect seen in the allogeneic transplant setting. This study further supports our prior work emphasising the importance of competent immune recovery post-ASCT in patients with cancer, since higher survival rates were observed in breast cancer patients with ALC у500 cells/l, as previously reported in NHL and MM. 6 
